Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Mark Lischner

Pulmonary Disease Roseville, CA Medical Doctor

NPI 1710924188 CMS profile 213262

5 Medical Plaza Dr, Suite 190, Roseville, CA 95661

Open in the dashboard

General payments

$11,189

586 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Mark Lischner of Roseville, CA is reported in the CMS Open Payments database as having received $11,189 across 586 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $69 3
2023 General $370 19
2022 General $2,145 94
2021 General $3,273 165
2020 General $2,601 145
2019 General $2,730 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Lischner
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Mark Lischner were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Mark Lischner Pulmonary Disease median Middle half National median
2019 $2,730 $377 $109–$1,340 $163
2020 $2,601 $230 $56–$907 $114
2021 $3,273 $269 $68–$1,072 $132
2022 $2,145 $390 $100–$1,457 $149
2023 $370 $419 $114–$1,659 $160
2024 $69 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,868 89 payments
  2. GlaxoSmithKline, LLC. $1,705 102 payments
  3. AstraZeneca Pharmaceuticals LP $1,137 65 payments
  4. ViiV Healthcare Company $441 23 payments
  5. Grifols USA, LLC $375 18 payments
  6. Gilead Sciences, Inc. $371 17 payments
  7. Actelion Pharmaceuticals US, Inc. $350 13 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $349 19 payments
  9. Merck Sharp & Dohme Corporation $340 18 payments
  10. AbbVie, Inc. $309 16 payments
  11. Other $3,944 206 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $11,018 583 payments
  2. Education $170 3 payments
Products named General payments · program years 2019–2024
  1. SPIRIVA RESPIMAT $1,031 51 payments
  2. TRELEGY ELLIPTA $851 52 payments
  3. OFEV $633 33 payments
  4. STIOLTO RESPIMAT Respiratory $605 31 payments
  5. BREZTRI $458 24 payments
  6. STIOLTO RESPIMAT Respiratory $429 16 payments
  7. AVYCAZ $414 22 payments
  8. GLASSIA $407 22 payments
  9. Prolastin-C Liquid $375 18 payments
  10. SYMBICORT $360 20 payments
  11. Other $7,797 391 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

586 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record